Naturally Occurring Adrenocortical Insufficiency – An Epidemiological Study Based on a Swedish-Insured Dog Population of 525,028 Dogs

J.M. Hanson, K. Tengvall, B.N. Bonnett, and Å. Hedhammar

Background: Naturally occurring adrenocortical insufficiency (NOAI) in dogs is considered an uncommon disease with good prognosis with hormonal replacement treatment. However, there are no epidemiological studies with estimates for the general dog population.

Objectives: To investigate the epidemiological characteristics of NOAI in a large population of insured dogs.

Animals: Data were derived from 525,028 client-owned dogs insured by a Swedish insurance company representing 2,364,652 dog-years at risk (DYAR) during the period between 1995–2006.

Methods: Retrospective cohort study. Incidence rates, prevalences, and relative risks for dogs with NOAI (AI with no previous claim for hypercortisolism), were calculated for the whole dog population, and for subgroups divided by breed and sex. Mortality rates were calculated and compared in dogs with NOAI and the remaining dogs overall.

Results: In total 534 dogs were identified with NOAI. The overall incidence was 2.3 cases per 10,000 DYAR. The relative risk of death was 1.9 times higher in dogs with NOAI than in dogs overall.

Conclusion and Clinical Importance: The data supports the existence of breed-specific differences in incidence rates of NOAI in dogs.

Key words: Addison’s disease; Hypoadrenocorticism; Incidence.

Abbreviations:

AI: adrenocortical insufficiency
CI: confidence interval
CKCS: Cavalier King Charles Spaniel
DYAR: dog-years at risk
FCI: Fédération Cynologique Internationale
IQR: interquartile range
IR: incidence rate
MHC: major histocompatibility complex
NOAI: naturally occurring adrenocortical insufficiency
NSDTR: Nova Scotia Duck Tolling Retriever
RR: relative risk
WHWT: West Highland White Terrier

From the Department of Clinical Sciences, Swedish University of Agricultural Sciences, (Hanson, Hedhammar); Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden (Tengvall); and B Bonnett Consulting, Georgian Bluffs, ON Canada (Bonnett).

The work was done at the Swedish University of Agricultural Sciences, Uppsala, Sweden.

Preliminary data on overall incidence rate and overall sex distribution was presented in a poster-abstract at the 6th International Conference on Advances in Canine and Feline Genomics and Inherited Diseases, 28th May to 1st June 2012, Visby, Sweden (poster abstract 18, p 85).

Jeanette Hanson, received ESV/Dechra Veterinary Products travel grants for Researcher in Veterinary Endocrinology 2014 for presenting abstract at the EVCIM congress 2014.

Corresponding author: Dr J. Hanson, Department of Clinical Sciences – Companion Animals, Swedish University of Agricultural Sciences, P.O. Box 7054, 750 07 Uppsala, Sweden; e-mail: jeanette.hanson@slu.se.

Submitted December 22, 2014; Revised September 19, 2015; Accepted November 16, 2015.

Copyright © 2015 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOJ: 10.1111/jvim.13815
and Portuguese Water Dog, with a reported occurrence up to 10% within the study populations.\textsuperscript{3,5–7} Reported sex distributions of NOAI vary by study. Initially, a significant overall female predominance was reported.\textsuperscript{1–4} However, subsequent breed-specific studies on Standard Poodles, Portuguese Water Dogs, and Bearded Collies failed to identify any significant difference by sex.\textsuperscript{5–7} The prognosis for dogs with NOAI on hormone replacement treatment is generally believed to be excellent, although there are few studies to support this.\textsuperscript{21,22}

In Sweden, there is a long tradition for dog owners to insure their animals for veterinary care, loss of function and death. The national dog population has an estimated size of 729,000 (±68,000) dogs. It is estimated that about 30–40% of the entire population is insured by 1 company – Agria Animal Insurance, Sweden.\textsuperscript{8,23–25} Most dogs are first insured as puppies and stay insured for veterinary care during life. Therefore, there are three major advantages to performing epidemiological studies on the insured dog population: large and known population at risk, inclusion of dogs from early in life, and long follow-up times.

Much remains unclear regarding AI in dogs. For example, it is unknown whether the reported variations in sex distribution represent true differences among breeds or are merely related to how the study-populations were selected.

In order to characterize the epidemiology of NOAI in dogs in a large, defined population of dogs at risk, data derived from Agria-insured dogs during an 11-year period (1995–2006), were analyzed. Incidence rates, relative risks, prevalence, and mortality rates were calculated for dogs with AI, without a previous claim for hypercortisolism.

Material and Methods

Animals

The study population consisted of dogs insured by Agria Animal Insurance, Sweden.\textsuperscript{4} The insurance process has previously been described in detail.\textsuperscript{24} Briefly, the insurance offers 2 main options; veterinary health care and life. The insurance for veterinary health care covers the costs exceeding a deductible chosen by the owner. This insurance may be continued throughout most of the life of the dog. When the dog is insured for life, the owner is reimbursed the monetary value of the dog in the case of death caused by disease or accident. Dogs in these data were not eligible for life insurance after 10 years of age. Most insured dogs were covered by both the veterinary care and life insurance. Dogs could enter the insurance program from 6 weeks of age until 6 years of age. Veterinary care events are recorded in the claims database when a preset deductible has been exceeded or in case of reported death with or without accompanying claim for life reimbursement. In cases where more than 1 diagnosis is reported on the same claim, only 1 diagnostic code is recorded in the database. Neuter status was not available. Breeds are classified based on the classification system by Fédération cynologique internationale (FCI) and Swedish Kennel Club breed classification system.

The insurance claim records for the period between January 1, 1995, and December 31, 2006 were accessed. Only dogs that were covered for both veterinary care and life were included in the study. Data collected from the records were breed, sex, date of birth, date of life insurance claim, date, and type of insurance claim (eg, veterinary care or life), and diagnostic code. Diagnostic codes were assigned by the attending veterinarian based on a standardized diagnostic register.\textsuperscript{26} There was only 1 code, addressed as “Addison’s disease” available for all conditions associated with AI. Further discrimination (eg, into primary and secondary AI or spontaneous and iatrogenic) was not possible. To decrease the potential for inclusion of dogs with iatrogenically caused AI, dogs were excluded if there was a history of claims for hypercortisolism before or within 20 days after the first claim for AI. For the remaining dogs (ie, dogs with a claim for AI excluding cases with a previous claim for hypercortisolism) the term NOAI is used in the present study.

For the cohort and breed-risk analysis, dogs were included, regardless of age at the time of insurance or during the study period (1995–2006). An individual was considered to be an incident case of AI at the time of the first recorded claim.

Analysis

Data analysis was performed with the R version 3.0.1 (www.r-project.org). Incidence rates (IRs) were calculated based on number of new cases and the exact times at risk. Incidence rates were expressed as number of cases per 10,000 dog-years at risk (DYAR). Relative risks (RRs) were calculated by dividing the IR for the population of interest with the IR of the residual population (excluding the population of interest). Prevalence was calculated at the end of the study period in dogs that were still insured at that time point. Mortality rate was calculated by expressing the number of dogs that were registered as dead within the study per 10,000 DYAR. The 95% confidence interval (CI) for prevalence was calculated with exact tests based on binomial distribution.\textsuperscript{27} Confidence intervals for IRs, mortality rates, and RRs were calculated with exact methods based on the Poisson distribution using the “epiR” package (version 0.9–58),\textsuperscript{b} and “exactci” package (version 1.2–1).\textsuperscript{28} For determination of level of significance, Bonferroni correction for multiple comparisons was applied, based on the number of breeds included in the comparison (n = 110 for RRs for breeds, n = 28 for sex distribution, n = 27 for mortality rates). P-values <.05 after Bonferroni correction were regarded as significant.

Results

The database included information on 525,028 dogs accounting for 2,364,652 DYAR. The dogs were divided into 354 breed categories. There were 260,552 (49.6%) female dogs, and 264,488 (50.4%) male dogs. Median age at enrollment in insurance was 77 days [interquartile range (IQR), 59–183 days]. Dogs contributed a median of 3.8 DYAR (IQR, 1.7–6.8 DYAR).

Incidence Rate: Overall and by Breed

Of the dogs with at least 1 claim for AI during the study period, 65 dogs had a previous claim for hypercortisolism and were excluded. The remaining dogs (n = 534) represented 110 different breed categories, including each of the 30 largest (based on DYAR) breed categories in the database. There were 74 Standard Poodles, 35 Bearded Collies, 26 mixed breed dogs, 25 Cairn Terriers, and 21 Golden Retrievers. The overall IR for
NOAI was 2.26 cases per 10,000 DYAR (95% CI, 2.07–2.46 cases per 10,000 DYAR). A significantly increased RR of NOAI compared with the residual population was seen in the Portuguese Water Dog, Standard Poodle, Bearded Collie, Cairn Terrier, and Cocker Spaniel (Fig 1). A significantly decreased RR for NOAI

| Breed                      | IR per 10,000 DYAR (95% CI) | RR (95% CI)   | P        |
|----------------------------|-----------------------------|---------------|----------|
| Portuguese Water Dog       | 64.5 (34.4 - 122)           | 29.0 (13.2 - 55.5) | 1.2 x 10⁻¹⁰ *** |
| Standard Poodle            | 33.4 (26.6 - 41.9)          | 17.0 (13.1 - 21.8) | <2.2 x 10⁻¹⁶ *** |
| Bearded Collie             | 15.8 (11.4 - 22.0)          | 7.43 (5.11 - 10.5) | <2.2 x 10⁻¹⁶ *** |
| Cairn Terrier              | 7.40 (5.03 - 10.9)          | 3.39 (2.17 - 5.06) | 7.6 x 10⁻⁷ *** |
| Great Dane                 | 7.23 (3.18 - 16.9)          | 3.22 (1.04 - 7.57) | 0.043    |
| Cocker Spaniel            | 6.45 (4.35 - 9.59)          | 2.94 (1.87 - 4.43) | 1.3 x 10⁻⁶ *** |
| Welsh Springer Spaniel     | 6.31 (2.96 - 13.7)          | 2.82 (1.03 - 6.17) | 0.044    |
| Riesenschnauzer            | 5.11 (2.25 - 11.9)          | 2.28 (0.736 - 5.34) | 0.15     |
| NSDTR                      | 5.08 (2.61 - 10.0)          | 2.27 (0.973 - 4.50) | 0.057    |
| English Setter             | 4.97 (2.19 - 11.6)          | 2.21 (0.715 - 5.19) | 0.16     |
| Wachtelhund                | 4.93 (2.54 - 9.72)          | 2.20 (0.946 - 4.37) | 0.066    |
| Poodle other               | 3.87 (2.51 - 5.97)          | 1.74 (1.05 - 2.72) | 0.031    |
| Belgian Tervuren           | 3.49 (1.54 - 8.14)          | 1.55 (0.501 - 3.64) | 0.45     |
| WHWT                       | 3.08 (1.52 - 6.34)          | 1.37 (0.547 - 2.84) | 0.51     |
| Shetland Sheepdog          | 2.97 (1.63 - 5.46)          | 1.32 (0.630 - 2.45) | 0.47     |
| Miniature Schnauzer        | 2.86 (1.41 - 5.89)          | 1.27 (0.508 - 2.63) | 0.64     |
| Bichon Frisé               | 2.84 (1.40 - 5.86)          | 1.26 (0.505 - 2.62) | 0.65     |
| Rottweiler                 | 2.76 (1.52 - 5.08)          | 1.23 (0.585 - 2.28) | 0.61     |
| All                        | 2.26 (2.07 - 2.46)          | 1             |          |
| English Springer Spaniel   | 2.18 (1.26 - 3.81)          | 0.965 (0.496 - 1.70) | 1        |
| Border Terrier             | 1.87 (0.824 - 4.37)         | 0.827 (0.267 - 1.94) | 0.88     |
| Flatcoated Retriever       | 1.60 (0.706 - 3.74)         | 0.707 (0.229 - 1.66) | 0.59     |
| Border Collie              | 1.56 (0.801 - 3.07)         | 0.684 (0.294 - 1.36) | 0.36     |
| Crossbred                  | 1.47 (1.01 - 2.15)          | 0.632 (0.409 - 0.938) | 0.020    |
| Golden Retriever           | 1.44 (0.946 - 2.20)         | 0.624 (0.383 - 0.963) | 0.031    |
| CKCS                       | 1.39 (0.684 - 2.85)         | 0.608 (0.243 - 1.26) | 0.23     |
| Labrador Retriever         | 1.13 (0.678 - 1.90)         | 0.487 (0.264 - 0.824) | 0.0045   |
| Drever                     | 0.785 (0.319 - 2.01)        | 0.343 (0.0931 - 0.883) | 0.020    |
| German Shepherd            | 0.662 (0.373 - 1.18)        | 0.278 (0.138 - 0.502) | 3.7 x 10⁻⁷ *** |
| Norwegian Elkhound         | 0.534 (0.165 - 1.93)        | 0.234 (0.0282 - 0.849) | 0.019    |
| Hamilton Hound             | 0.303 (0.0733 - 1.67)       | 0.132 (0.00335 - 0.741) | 0.0093   |
| Dachshund                  | 0.294 (0.954 - 0.685)       | 0.122 (0.0394 - 0.286) | 1.1 x 10⁻¹⁰ *** |
| Yorkshire Terrier          | 0 (0.00 - 1.99)             | 0.00 (0.00 - 0.875) | 0.030    |

Fig 1. Incidence rate of adrenocortical insufficiency (AI), excluding cases with a previous claim for hypercortisolism, in a population of 525,028 insured dogs. Data from breeds with ≥5 cases of AI, and from breeds that had a reduced relative risk (RR) with P < .05 before Bonferroni correction. NSDTR, Nova Scotia Duck Tolling Retriever; CKCS, Cavalier King Charles Spaniel; WHWT, West Highland White Terrier; DYAR, dog years at risk; IR, incidence rate, cases per 10,000 DYAR; CI, confidence interval; RR, relative risk of AI within the breed in comparison with the other breeds combined. Asterisks represent level of significance after conservative correction (Bonferroni, n = 115) for multiple testing: *P < .05; **P < .01; ***P < .001.
compared with the residual population was seen in the German Shepherd Dog, and Dachshund.

**Prevalence**

At the end of the study period 191,434 dogs were alive. Of these, 166 dogs had at least 1 claim of NOAI, resulting in an overall prevalence of 0.0867% (95% CI, 0.0740% to 0.101%). The prevalence was 1.17% (95% CI, 1.21% to 2.35%) in Standard Poodles, 1.16% (95% CI, 0.240% to 3.35%) in Portuguese Water Dogs, 0.417% (95% CI, 0.200% to 0.766%) in Cairn Terriers and 0.322% (95% CI, 0.0880% to 0.825%) in Bearded Collies.

**Sex**

Of 534 dogs with NOAI, 64% (95% CI, 60% to 68%) were females, and 36% (95% CI, 32% to 40%) were males. The overall IR in female dogs was 3.45 cases per 10,000 DYAR (95% CI, 3.10–3.84 cases per 10,000 DYAR). The overall IR in male dogs was 1.86 cases per 10,000 DYAR (95% CI, 1.61–2.15 cases per 10,000 DYAR). The RR in female dogs compared with male dogs overall was 1.85 (95% CI, 1.55–2.22; P < .001) (Fig 2). Sex proportion varied by breed. After Bonferroni correction, female predisposition within the breed was statistically significant in Golden Retrievers. In Standard Poodles and mixed breed dogs among others, incidence rates were not significantly different between sexes (Fig 2).

**Mortality Rates**

Of the dogs that were registered as dead within the study period, median age at death for dogs with NOAI was 6.90 years (IQR, 4.33–8.46 years) and median age at death for the other dogs overall in the same period was 6.53 years (IQR, 3.56–8.60 years). Of the 534 dogs with NOAI, 212 dogs were reported to die within the study period. The mortality rate because of all causes in dogs with NOAI was 664 (95% CI, 578–760) dogs per 10,000 DYAR. The overall IR in male dogs was 1.85 years (IQR, 1.55–2.22; P < .001) (Fig 2). Sex proportion varied by breed. After Bonferroni correction, female predisposition within the breed was statistically significant in Golden Retrievers. In Standard Poodles and mixed breed dogs among others, incidence rates were not significantly different between sexes (Fig 2).

**Discussion**

This study reports epidemiological data for NOAI during an 11-year period in a population of more than 500,000 insured dogs. The uniqueness of the study lies in it being based on a large population of insured dogs. Overall and breed-specific incidence rates are presented. Sex variation was only shown in some breeds, and a higher mortality rate was identified in dogs with AI compared with other dogs. The results from this study support the existence of breed-specific differences in the behavior of AI in dogs.

The overall incidence rate of AI in this study was 2.3 cases per 10,000 DYAR. The overall prevalence was almost 0.09%, which is in the magnitude of previous prevalence estimates of 0.09–0.32% for both naturally occurring and iatrogenic AI, and of 0.28% for NOAI. This also matches a previous statement of a 100 times higher prevalence in the dog than in humans. The highest IRs and RRs were, as anticipated, found in the Portuguese Water Dog, Standard Poodle and the Bearded Collie. However, the figures for estimated prevalence by breed in the present report are lower than previously reported occurrences; 1.2% versus 8.6% for the Standard Poodle, 0.32% versus 4.5% to 9.4% in the Bearded Collie, and 1.2% versus 7.0% in the Portuguese Water Dog. The most probable explanation for this difference is that the different studies look at different subsets of the overall AI picture. The present study is based on a large cohort of dogs, which represent an insured dog population comprising approximately 30–40% of the national population during the time of the study. Dogs were included at an early age (median less than 3 months of age, interquartile range about 6 months of age), which is reflected by the median contribution of 3.8 DYAR per dog. Previous calculations were positively biased with the respect to proportion of dogs with NOAI, although other factors may contribute such as differences in familial/bloodlines within a breed between countries. The present results affirm the previously reported increased risk of developing NOAI in the Cairn Terrier. In contrast to previous reports, the Cocker Spaniel breed was associated in the present study with a significantly increased risk of developing NOAI. The Cocker Spaniel breed is known to be predisposed for other immune-mediated diseases such as immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, and reportedly hypothyroidism. Therefore, it is reasonable to assume that the adrenal gland would be another target of the increased tendency for autoimmune reactions seen in the Cocker Spaniel breed. The German Shepherd Dog is another breed known to be predisposed to immune-related disorders, for example, atopic dermatitis, unspecific dermatitis, enteritis, and exocrine pancreatic atrophy. In contrast to Cocker Spaniels, however, the German Shepherd dogs had a low risk of NOAI. A possible explanation for the difference in the risk of AI between the Cocker Spaniel and the German Shepherd Dog may be explained by dissimilarities in the underlying pathophysiological mechanisms for the immunological reactions. For example, it was recently shown that atopic dermatitis may be related to a defect in skin integrity because of an altered expression of the desmosome protein Plakophilin 2. In Cocker Spaniels, however, NOAI may be related to the class of major
histocompatibility complex (MHC) which in humans is shown to increase the likelihood of the development of autoimmune AI \(^{29,37-39}\) and autoimmune diseases in general. \(^{40}\)

In this study, NOAI was generally more frequently diagnosed in female dogs. However, incidence rates between sexes varied by breed ranging from an almost 10 times higher risk of developing NOAI in female Golden Retrievers than in male Golden Retriever dogs to an equal risk of developing NOAI between sexes in the Standard Poodle. As the calculations in this study are based on dogs in the same population, the evidence
is strong that there is a true difference in sex predisposition between some breeds. Furthermore, for the first time we show that in the Golden Retriever more females than male dogs get NOAI although the breed was not at increased risk of developing NOAI compared with all breeds, combined. This may have important future implications. In people, it is estimated that approximately 40% of human patients with the autoimmune adrenalitis have sporadically occurring, so-called “isolated” form of primary AI. Adrenocortical insufficiency in the Golden Retriever thereby may prove to be a model for isolated AI in women. Likewise the Stan-

| Breed                      | IR death per 10,000 DYAR (95% CI) | RR death (95%CI) | P   |
|----------------------------|----------------------------------|------------------|-----|
| Bichon Frisé              | 1070 (473 - 2510)                | 6.01 (1.94 - 14.1) | 0.0034 |
| Miniature Schnauzer       | 931 (338 - 2720)                 | 5.68 (1.17 - 16.7) | 0.034 |
| WHWT                      | 923 (335 - 2700)                 | 4.92 (1.01 - 14.5) | 0.049 |
| Cairn Terrier             | 716 (403 - 1280)                 | 4.32 (2.14 - 7.79) | 1.6 x 10^{-4} ** |
| Border Collie             | 1020 (371 - 2990)                | 4.12 (0.849 - 12.1) | 0.075 |
| English Setter            | 1300 (473 - 3800)                | 4.03 (0.826 - 11.9) | 0.081 |
| Wachtelhund               | 1030 (484 - 2250)                | 3.62 (1.32 - 7.93) | 0.015 |
| Poodle other              | 734 (378 - 1450)                 | 3.35 (1.44 - 6.63) | 0.0066 |
| Crossbred                 | 979 (565 - 1710)                 | 2.93 (1.51 - 5.12) | 0.0022 |
| Bearded Collie            | 790 (508 - 1230)                 | 2.92 (1.74 - 4.60) | 1.2 x 10^{-4} ** |
| Portuguese Water Dog      | 453 (140 - 1640)                 | 2.84 (0.323 - 11.5) | 0.34 |
| Golden Retriever          | 600 (309 - 1180)                 | 2.83 (1.22 - 5.59) | 0.017 |
| Shetland Sheepdog         | 611 (248 - 1560)                 | 2.68 (0.729 - 6.90) | 0.13 |
| Cocker Spaniel            | 838 (472 - 1500)                 | 2.29 (1.14 - 4.12) | 0.021 |
| Labrador Retriever        | 523 (212 - 1340)                 | 2.26 (0.616 - 5.80) | 0.21 |
| Riesen Schnauzer          | 1220 (497 - 3140)                | 2.23 (0.604 - 5.73) | 0.22 |
| All                       | 664 (578 - 760)                  | 1.92 (1.67 – 2.20) | <2.2 x 10^{-16} *** |
| Border Terrier            | 282 (68.3 - 1570)                | 1.85 (0.0466 - 10.3) | 0.84 |
| Great Dane                | 1940 (855 - 4530)                | 1.77 (0.574 - 4.15) | 0.31 |
| Standard Poodle           | 371 (235 - 586)                  | 1.71 (1.01 - 2.74) | 0.047 |
| Welsh Springer Spaniel    | 291 (70.4 - 1620)                | 1.44 (0.0363 - 8.13) | 1 |
| CKCS                      | 709 (258 - 2070)                 | 1.39 (0.287 - 4.07) | 0.73 |
| Belgian Tervuren          | 457 (111 - 2540)                 | 1.23 (0.0311 - 6.89) | 1 |
| NSDTR                     | 377 (117 - 1360)                 | 1.23 (0.149 - 4.47) | 0.97 |
| Flatcoated Retriever      | 595 (184 - 2150)                 | 1.16 (0.140 - 4.19) | 1 |
| German Shepherd Dog       | 646 (284 - 1510)                 | 1.10 (0.358 - 2.57) | 0.95 |
| English Springer Spaniel  | 241 (74.6 - 872)                 | 0.841 (0.102 - 3.05) | 1 |
| Rottweiler                | 340 (105 - 1230)                 | 0.567 (0.0687 - 2.05) | 0.63 |

**Fig 3.** Mortality rate of adrenocortical insufficiency (AI) by breed in a population of 528,028 insured dogs. Dogs with a previous claim for hypercortisolism were excluded. Data are shown for breeds with ≥ 5 cases of AI. NSDTR, Nova Scotia Duck Tolling Retriever; CKCS, Cavalier King Charles Spaniel; WHWT, West Highland White Terrier; IR, incidence rate; CI, confidence interval; RR, relative risk of death of AI dogs in comparison with overall within the breed. Asterisks represent level of significance after conservative correction (Bonferroni, n = 28) for multiple testing: *P < .05; **P < .01; ***P < .001.
standard Poodle and Bearded Collie may prove to be models for other forms of inherited AI in man.44 Information about castration status of the dogs in the present study is unknown. However, most Swedish dogs are intact (78%).42 It can therefore be assumed that most of the dogs in the insurance database are intact, which may have influenced the risks of developing disease positively or negatively.1,3

The mortality rate was significantly higher in dogs with NOAI compared with dogs overall, which may indicate that there may be problems encountered during the management of the disease that may lead to the early death of the dog or may make the owner inclined to opt for euthanasia. After Bonferroni correction, Cairn Terriers, and Bearded Collies with NOAI had a significantly higher mortality rate than dogs without NOAI of the same breed. For breeds with small number of NOAI cases, lack of power can be a reason for not being able to detect a difference. However, in the breed with most registered cases with NOAI, the Standard Poodle, mortality rate in NOAI dogs was not significantly higher than for other dogs of that breed, after Bonferroni correction. Breed-dependent differences may exist.

Our findings in the dog reflect what has earlier been reported in humans. After an initial report on excellent survival on glucocorticoid and mineralocorticoid hormone replacement treatment,43 there was paucity of prognostic studies for AI in people. Recently, 2 Scandinavian studies on long-term prognosis were published, reporting a higher risk of mortality during the early time-period after detection of Addison’s disease,44 and an increased risk of mortality was identified in patients younger than 40 years.45 Additionally, a reduction in life expectancy was reported in both women (reduction by 11.2 years) and men (reduction by 3.2 years) and in women (reduction by 3.2 years).45 Further studies are needed to investigate the underlying characteristics, and breed differences in the increased mortality rate in dogs with AI.

There are a number of limitations to this study some of which, depending on the cause, have contributed to either an increased or decreased incidence rate. In order to include dogs with a lifetime longer than the total duration of the study period (ie, 10 years), the study also includes dogs that were born before the study period. Therefore, for some dogs, the first claim of diagnosis within the study may not be the true first claim of that dog, which may contribute to a slight overestimation of the incidence rates. The main aim of the study was to investigate the incidence rate of NOAI, therefore dogs with a previous history of claims for hypercortisolism were excluded. Still there may be dogs included that may have been iatrogenically caused by sudden withdrawal of glucocorticoid treatment. There are no pathognomonic signs for AI. Therefore, the diagnosis of AI is dependent upon a test measuring the adrenocortical hormone-producing capacity, most commonly the ACTH-stimulation test.4 Because the present study is based on data from many different veterinarians, irrespective of level of specialization, there is a risk that dogs with AI have been misdiagnosed as other more common disorders such as renal failure or gastrointestinal disease, alternatively AI could have been erroneously diagnosed. Although the study period starts at a time when important and extensive articles on AI were published,1,3,21 which most probably contributed to an increased awareness of the existence of the disorder among veterinarians world-wide, the study period extended over a decade, during which there may have been variation in the degree of awareness of and capability to diagnose the disease. Thus, the true incidence in the general dog population may be higher or lower than presented here. There may also be a negative bias for the diagnosis in breeds that is not usually associated with NOAI, and young dogs that died before 6 weeks of age, which is the age limit for individual dog insurance. Other potential risks for underestimation of disease incidence are that dogs were diagnosed with the disease without exceeding the set deductible, or that AI was not registered as first diagnosis, and therefore not included in the database. However, the expected costs for initial work up including veterinary consult, blood work, ACTH-stimulation test, and control visits will likely exceed the standard deductible. Likewise, due to its severity, AI is likely to be chosen as first diagnosis at time of diagnosis or at control visits. With increased awareness of the disease and recognition of its many facets of clinical presentation, it can be assumed that increased testing for the disease will result in increased incidence rates. Finally, even though the interquartile ranges are largely overlapping, there is a slightly higher median age at death of the NOAI dogs than may have contributed to some degree to the overall increased mortality rate found. However, at the end of the study, the median age of breeds contributing with NOAI cases was higher than the median age of all dogs (data not shown). Thus we do not expect that diagnosis age distribution to be a major determining factor for the increased mortality rate observed in NOAI dogs in this study.

In summary, in addition to being the largest epidemiological study of NOAI in dogs reported in the literature, the present study is based on a large and well-defined population of dogs that are reasonably representative of the general dog population. Importantly, we present data supporting the presence of breed-specific differences in NOAI regarding incidence rates, sex distribution and mortality rates, suggesting the existence of different subtypes of NOAI in the dog, analogous to what is known in people. More studies are needed to further characterize AI in dogs with respect to possible breed and sex differences, and long-term survival during treatment.

Footnotes

a Agria Pet Insurance, Stockholm, Sweden
b EpiR, An R package for the analysis of epidemiological data. Stevenson M, Sanchez J, Thornton, R. http://epicentre.massey.ac.nz
**Acknowledgments**

*Financial Support:* This study was supported by grants from the Swedish Research Council and the Foundation for Research, Agria Insurance Company. The contribution of the Agria Insurance Company by making part of their database available for the research is highly appreciated. The authors thank Prof. Agneta Egenvall, Mikael Andersson Franko, Marcin Kierczak for statistical advice, and Hanna Bremer for input and discussions.

*Conflict of Interest Declaration:* Brenda N. Bonnett consults with Agria insurance company on various projects. The Agria insurance company funded work leading to the development of the insurance data base used as data source in the study. This study was supported by grants from the Swedish Research Council and the Foundation for Research, Agria Insurance Company.

*Off-label Antimicrobial Declaration:* Authors declare no off-label use of antimicrobials.

**References**

1. Kelch WJ. Canine Hypoadrenocorticism (Canine Addison's disease): History, Contemporary Diagnosis by Practicing Veterinarians, and Epidemiology [dissertation]. Knoxville: University of Tennessee; 1996.

2. Kelch WJ, Lynn RC, Smith CA, New JC. Canine hypoadrenocorticism (Addison's disease). Comp Small Anim Pract 1998;20:921–934.

3. Peterson ME, Kintzer PP, Kass PH. Pretreatment clinical and laboratory findings in dogs with hypoadrenocorticism: 225 cases (1979–1993). J Am Vet Med Assoc 1996;208:85–91.

4. Feldman EC, Nelson RW. Hypoadrenocorticism (Addison's disease). In Canine and Feline Endocrinology and Reproduction, 3rd ed. St. Louis: Saunders; 2004:394–439.

5. Famula TR, Belanger JM, Oberbauer AM. Heritability and complex segregation analysis of hypoadrenocorticism in the standard poodle. J Small Anim Pract 2003;44:8–12.

6. Oberbauer AM, Benemann KS, Belanger JM, et al. Inheritance of hypoadrenocorticism in bearded collies. Am J Vet Res 2002;63:643–647.

7. Oberbauer AM, Bell JS, Belanger JM, Famula TR. Genetic evaluation of Addison’s disease in the Portuguese water dog. BMC Vet Res 2006;2:15.

8. Sell E. Health Committee Report. Bearded Collie Club America National Specialty; 1998.

9. Slater MR. The 2005 Portuguese Water Dog Health Survey: Final Report. Portuguese Water Dog Club of America; 2006.

10. Hadlow WJ. Adrenal cortical atrophy in the dog: report of three cases. Am J Pathol 1953;29:353–361.

11. Siegel ET, Schrayer HF, Fidler I. Clinico-pathologic conference. J Am Vet Med Assoc 1967;150:423–433.

12. Frank CB, Valentin SY, Scott-Moncrieff JCR, Miller MA. Correlation of inflammation with adrenocortical atrophy in canine adrenalsitis. J Comp Pathol 2013;149:268–279.

13. Mulnix JA. Hypoadrenocorticism in the dog. J Am Anim Hosp Assoc 1971;7:220–241.

14. Bistner S, de Lahunta A, Lorenz M. Generalized cryptococcosis in a dog. Cornell Vet 1971;61:440–457.

15. Kook PH, Grest P, Raute-Kreinsen U, et al. Addison’s disease due to bilateral adrenal malignancy in a dog. J Small Anim Pract 2010;51:335–336.

16. Willard MD, Schall WD, Nachreiner RF, Shelton DG. Hypoadrenocorticism following therapy with o, p-DDD for hyperadrenocorticism in four dogs. J Am Vet Med Assoc 1982;180:638–641.

17. Chapman PS, Kelly DF, Archer J, et al. Adrenal necrosis in a dog receiving triolostane for the treatment of hyperadrenocorticism. J Small Anim Pract 2004;45:307–310.

18. Ramsey IK, Richardson J, Lenard Z, et al. Persistent isolated hypocortisolism following brief treatment with triolostane. Aust Vet J 2008;86:491–495.

19. Hanson JM, Teske E, Voorhout G, et al. Prognostic factors for outcome after transphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism. J Neurosurg 2007;107:830–840.

20. Chase K, Lawler DF, McGill LD, et al. Age relationships of postmortem observations in Portuguese water dogs. Age (Dordr) 2011;33:461–473.

21. Kintzer PP, Peterson ME. Treatment and long-term follow-up of 205 dogs with hypoadrenocorticism. J Vet Intern Med 1997;11:43–49.

22. Bates JA, Shott S, Schall WD. Lower initial dose desoxycorticosterone pivalate for treatment of canine primary hypoadrenocorticism. Aust Vet J 2013;91:77–82.

23. Bonnett BN, Egenvall A. Age patterns of disease and death in insured Swedish dogs, cats and horses. J Comp Pathol 2010;142 (Suppl 1):S33–S38.

24. Egenvall A, Bonnett BN, Olson P, Hedhammar A. Gender, age, breed and distribution of morbidity and mortality in insured dogs in Sweden during 1995 and 1996. Vet Rec 2000;146:519–525.

25. Statistiska Centralbyrån. Förekomst av sällskapsdjur - främst hund och katt - i svenska hushåll. Statistiska Centralbyrån 2006. Swedish.

26. Svenska Djursjukhusföreningen. Diagnosregistret. Olson P, Kängström LE, eds. Taberg: Diagnosregister 1993. Swedish.

27. Collett D. Exact methods. In Modelling Binary Data, 2nd ed. Boca Raton: Chapman & Hall/CRC; 2003:303–324.

28. Fay MP. Two-sided exact tests and matching confidence intervals for discrete data. R J 2010;2:53–58.

29. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet 2014;383:2152–2167.

30. Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988–1996). J Am Anim Hosp Assoc 1999;35:384–391.

31. Miller SA, Hohenhaus AE, Hale AS. Case-control study of blood type, breed, sex, and bacteremia in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc 2004;224:232–235.

32. Grindem CB, Breitschwerdt EB, Corbett WT, Jans HE. Epidemiologic survey of thrombocytopenia in dogs: a report on 978 cases. Vet Clin Pathol 1991;20:38–43.

33. Lewis DC, Meyers KM. Canine idiopathic thrombocytopenic purpura. J Vet Intern Med 1996;10:207–218.

34. Nachreiner RF, Refsal KR, Graham PA, Bowman MM. Prevalence of serum thyroid hormone autoantibodies in dogs with autoimmune thyroiditis. J Am Vet Med Assoc 2002;220:466–471.

35. Vilson A, Bonnett B, Hansson-Hamlin H, Hedhammar A. Disease patterns in 32,486 insured German shepherd dogs in Sweden during 1995 and 1996. Vet Rec 2013;173:116.

36. Miller SA, Hohenhaus AE, Hale AS. Case-control study of blood type, breed, sex, and bacteremia in dogs with immune-mediated hemolytic anemia. J Am Vet Med Assoc 2004;224:232–235.

37. Massey J, Boag A, Short AD, et al. MHC class II association study in eight breeds of dog with hypoadrenocorticism. PLoS Genet 2013;9:e1003475.

38. Short AD, Boag A, Catchpole B, et al. A candidate gene analysis of canine hypoadrenocorticism in 3 dog breeds. J Hered 2013;104:807–820.
39. Mitchell AL, Pearce SHS. Autoimmune Addison disease: pathophysiology and genetic complexity. Nat Rev Endocrinol 2012;8:306–316.

40. Tsai S, Santamaria P. MHC class II polymorphisms, autoreactive T-cells, and autoimmunity. Front Immunol 2013;4:321.

41. Husebye ES, Allolio B, Arlt W, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med 2014;275:104–115.

42. Statistiska Centralbyrån. Hundar, katter och andra sällskapsdjur 2012. Statistiska Centralbyrån 2012. Swedish.

43. Dunlop D. Eighty-six cases of Addison’s disease. Br Med J 1963;2:887–891.

44. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison’s disease: a population-based study. J Clin Endocrinol Metab 2006;91:4849–4853.

45. Erichsen MM, Lovás K, Fougner KJ, et al. Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death. Eur J Endocrinol 2009;160:233–237.